WILMINGTON, Del., June 20, 2026
Incyte Biosciences Japan G.K. has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), marking an important advancement for patients facing one of the most aggressive forms of non-Hodgkin lymphoma. The approval provides a new therapeutic option for patients whose disease has returned or failed to respond to previous treatments and who are not eligible for autologous stem cell transplant (ASCT). The regulatory decision strengthens Incyte’s growing oncology portfolio and reflects increasing global recognition of tafasitamab-based treatment strategies in hematologic malignancies. DLBCL remains the most common subtype of non-Hodgkin lymphoma worldwide, and while many patients initially respond to therapy, outcomes for relapsed or refractory disease remain challenging, creating a significant unmet medical need. The approval is expected to expand access to innovative targeted therapies for patients across Japan and improve treatment outcomes in a difficult-to-treat population.
Clinical Trials Demonstrate Strong Response Rates
The Japanese approval is supported by positive findings from both the international L-MIND Phase II trial and the domestic J-MIND Phase Ib/II study, which evaluated the efficacy and safety of Minjuvi combined with lenalidomide in patients with relapsed or refractory DLBCL. In the pivotal L-MIND study, the combination achieved an overall response rate (ORR) of 58.8%, including a complete response rate of 41.3% and a partial response rate of 17.5%. Long-term follow-up data demonstrated durable clinical benefits, with the median duration of response not reached after more than 44 months of observation. The Japanese J-MIND trial further reinforced these findings, reporting an impressive 71.4% response rate, including a complete response rate of 45.2% and a partial response rate of 26.2%.
Researchers reported that the therapy demonstrated clinically meaningful efficacy with manageable side effects, primarily involving neutropenia and thrombocytopenia. These strong response rates highlight the potential of the regimen to significantly improve outcomes for patients who have limited treatment alternatives.
Targeted CD19 Therapy Expands Precision Oncology Options
Advertisement
Minjuvi contains tafasitamab, a humanized CD19-targeting monoclonal antibody engineered to enhance immune-mediated destruction of malignant B cells. The therapy utilizes advanced Fc-modification technology designed to strengthen mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). By specifically targeting CD19-expressing cancer cells, the treatment provides a precision medicine approach that complements existing lymphoma therapies. The approval represents the second regulatory authorization for Minjuvi in Japan, following its earlier approval in combination with rituximab and lenalidomide for relapsed or refractory follicular lymphoma.
The latest approval further expands the role of targeted immunotherapy in hematologic cancers and reflects growing confidence in antibody-based treatment strategies. As researchers continue exploring innovative combinations and new indications, tafasitamab is emerging as an important component of next-generation lymphoma treatment paradigms.
Advancing Treatment for Aggressive Blood Cancers
The approval underscores Incyte’s commitment to advancing innovative therapies for patients with hematologic malignancies and other serious diseases. With DLBCL accounting for a substantial proportion of non-Hodgkin lymphoma diagnoses globally, expanding access to effective targeted therapies remains a priority for healthcare providers and regulators. Experts believe the approval of Minjuvi combined with lenalidomide offers physicians a valuable new option for managing patients who have exhausted standard therapies or are unsuitable candidates for stem cell transplantation.
The decision also highlights the importance of international and regional clinical research programs in bringing novel therapies to patients more rapidly. As precision oncology continues to reshape cancer treatment, the availability of innovative antibody-based therapies such as Minjuvi may help improve survival outcomes and quality of life for patients facing aggressive blood cancers.
Source: Incyte press release
